ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed
Diego A. Vicente
Matched on ORCID iD 0000-0001-8613-9027; OpenAlex author ID A5076708816. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper
Papers 6
- Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model. Co-author DOI 10.1016/j.surg.2023.05.011↗
- Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthotopic murine pancreatic cancer model. Co-author DOI 10.1007/s12672-022-00483-4↗
- Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-09518-y↗
- Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model. First author DOI 10.1016/j.surg.2020.04.059↗
- Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.jss.2019.04.090↗
- Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model. Co-author DOI 10.1158/2326-6066.cir-19-0101↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jayanth S. Shankara Narayanan · 4 shared papers, 2019–2023 · strength 0.54
- Paper Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a m… DOI 10.1016/j.surg.2023.05.011↗
- Paper Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthoto… DOI 10.1007/s12672-022-00483-4↗
- Paper Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model. DOI 10.1016/j.surg.2020.04.059↗
- Rebekah Ruth White · 4 shared papers, 2019–2023 · strength 0.54
- Paper Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a m… DOI 10.1016/j.surg.2023.05.011↗
- Paper Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthoto… DOI 10.1007/s12672-022-00483-4↗
- Paper Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model. DOI 10.1016/j.surg.2020.04.059↗
- Steven C. Katz · 3 shared papers, 2020–2023 · strength 0.45
- Paper Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a m… DOI 10.1016/j.surg.2023.05.011↗
- Paper Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthoto… DOI 10.1007/s12672-022-00483-4↗
- Paper Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model. DOI 10.1016/j.surg.2020.04.059↗
- Partha Ray · 3 shared papers, 2019–2022 · strength 0.36
- Paper Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthoto… DOI 10.1007/s12672-022-00483-4↗
- Paper Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model. DOI 10.1016/j.surg.2020.04.059↗
- Paper Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Mur… DOI 10.1158/2326-6066.cir-19-0101↗
- Benedict A. Capacio · 2 shared papers, 2020–2023 · strength 0.29
- Suna Erdem · 2 shared papers, 2020–2022 · strength 0.26
- Matthew H. G. Katz · 2 shared papers, 2019–2021 · strength 0.22
- Andrew J. Lee · 2 shared papers, 2019–2021 · strength 0.22
- Michael P. Kim · 2 shared papers, 2019–2021 · strength 0.22
- Jeffrey E. Lee · 2 shared papers, 2019–2021 · strength 0.22
- Ching-Wei David Tzeng · 2 shared papers, 2019–2021 · strength 0.22
- Michael Geoffrey White · 1 shared paper, 2021 · strength 0.13
- Naruhiko Ikoma · 1 shared paper, 2021 · strength 0.13
- Stephen Philip Schoenberger · 1 shared paper, 2019 · strength 0.10
- Andrew D. Rhim · 1 shared paper, 2019 · strength 0.09
- Anirban Maitra · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.